Skip to main content

Table 3 In vitro antimicrobial activity of the synthesized compounds

From: Design, synthesis and biological potential of heterocyclic benzoxazole scaffolds as promising antimicrobial and anticancer agents

Compound no.

Antimicrobial results (MIC = µM)

Bacterial species

Fungal species

BS

SA

EC

ST

KP

AN

CA

1

60.9

60.9

121.8

60.9

60.9

60.9

30.5

2

30.5

60.9

60.9

30.5

60.9

60.9

60.9

3

31.6

63.2

63.2

31.6

63.2

63.2

31.6

4

28.1

28.1

14.0

28.1

56.2

28.1

28.1

5

13.3

53.3

106.7

26.7

53.3

53.3

53.3

6

30.2

30.2

30.2

60.4

30.2

30.2

30.2

7

27.3

54.5

54.5

54.5

27.3

54.5

27.3

8

15.9

63.5

63.5

63.5

63.5

31.8

63.5

9

15.9

63.5

15.9

63.5

31.8

31.8

31.8

10

31.3

31.3

31.3

31.3

31.3

31.3

31.3

11

16.3

65.2

16.3

32.6

32.6

32.6

65.2

12

56.3

56.3

56.3

56.3

56.3

112.5

56.3

13

57.6

57.6

57.6

57.6

57.6

115.1

57.6

14

28.1

56.3

14.1

28.1

56.3

56.3

28.1

15

15.9

63.5

15.9

31.8

63.5

31.8

31.8

16

14.1

56.3

56.3

56.3

56.3

28.1

56.3

17

31.8

63.5

15.9

31.8

63.5

31.8

63.5

18

16.3

65.2

32.6

32.6

32.6

32.6

32.6

19

15.6

62.5

62.5

62.5

62.5

31.3

31.3

20

31.3

62.5

62.5

62.5

62.5

125.0

125.0

Ofloxacin

17.3

34.6

34.6

34.6

34.6

Fluconazole

40.8

40.8

  1. BS: Bacillus subtilis; SA: Staphylococcus aureus; EC: Escherichia coli; ST: Salmonella typhi; KP: Klebsiella pneumoniae; AN: Aspergillus niger; CA: Candida albicans